La néphrectomie est-elle indispensable en cas de métastases ?

25 mars 2010

Auteurs : T. Lebret, Y. Neuzillet, G. Pignot
Référence : Prog Urol, 2010, 20, S33, suppl. S1




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Méjean A., Lebret T. Prise en charge du cancer du rein métastatique Prog Urol 2008 ;  18 : 298-308
Oliver R.T., Nethersell A.B., Bottomley J.M. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma Br J Urol 1989 ;  63 : 128-131 [cross-ref]
Snow R.M., Schellhammer P.F. Spontaneous regression of metastatic renal cell carcinoma Urology 1982 ;  20 : 177-181 [cross-ref]
Freed S.Z., Halperin J.P., Gordon M. Idiopathic regression of metastases from renal cell carcinoma J Urol 1977 ;  118 : 538-542 [cross-ref]
Ng C.S., Novick A.C., Tannenbaum C.S., Bukowski R.M., Finke J.H. Mechanisms of immune evasion by renal cell carcinoma: tumorinduced T-lymphocyte apoptosis and NFkappaB suppression Urology 2002 ;  59 : 9-14 [inter-ref]
Marcus S.G., Choyke P.L., Reiter R., Jaffe G.S., Alexander R.B., Linehan W.M., et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy J Urol 1993 ;  150 : 463-466 [cross-ref]
Dekernion J.B., Ramming K.P., Smith R.B. The natural history of metastatic renal cell carcinoma: a computer analysis J Urol 1978 ;  120 : 148-152 [cross-ref]
Mickisch G.H., Garin A., Van Poppel H., De Prijck L., Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 2001 ;  358 : 966-970 [cross-ref]
Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 2001 ;  345 : 1655-1659 [cross-ref]
Flanigan R.C., Mickisch G.H., Sylvester R., Tangen C.M., Van Poppel H., Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 2004 ;  171 : 1071-1076 [cross-ref]
Pantuck A.J., Belldegrun A.S., Figlin R.A. Nephrectomy and interleukn-2 for metastatic renal-cell carcinoma N Engl J Med 2001 ;  345 : 1711-1712 [cross-ref]
Wagner J.R., Walther M.M., Linehan W.M., White D.E., Rosenberg S.A., Yang J.C. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place J Urol 1999 ;  162 : 43-45 [cross-ref]
Belldegrun A., Shvarts O., Figlin R.A. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma Cancer J Sci Am 2000 ;  6 : 88-92
Fujikawa K., Matsui Y., Miura K., Kobayashi T., Oka H., Fukuzawa S., Takeuchi H. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy J Urol 2000 ;  164 : 673-675 [cross-ref]
Dadian G., Riches P.G., Henderson D.C., Taylor A., Moore J., Atkinson H., Gore M.E. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy Br J Urol 1994 ;  74 : 15-22 [cross-ref]
Wunderlich H., Steiner T., Kosmehl H., Junker U., Reinhold D., Reichelt O., et al. Increased transforming growth factor β-1 plasma level in patients with renal cell carcinoma: a tumorspecific marker? Urol Int 1998 ;  60 : 205-207 [cross-ref]
Spencer W.F., Linehan W.M., Walther M.M., Haas G.P., Lotze M.T., Topalian S.L., et al. Immunotherapy with interleukin-2 and interferon in patients with metastatic renal cell cancer in situ primary cancers: a pilot study J Urol 1992 ;  147 : 24-30 [cross-ref]
Wood C.G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma Urol Clin North Am 2003 ;  30 : 581-588 [inter-ref]
Gatenby R.A. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cell cancer after cytoreductive nephrectomy Cancer Res 2002 ;  62 : 5218-5222
Bennett R.T., Lerner S.E., Taub H.C., Dutcher J.P., Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma J Urol 1995 ;  154 : 32-34 [cross-ref]
Mani S., Todd M.B., Katz K., Poo W.J. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers J Urol 1995 ;  154 : 35-40 [cross-ref]
Levy D.A., Swanson D.A., Slaton J.W., Ellerhorst J., Dinney C.P. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma J Urol 1998 ;  159 : 1168-1173 [cross-ref]
Russo P. Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy Nat Clin Pract Urol 2004 ;  1 : 26-30 [cross-ref]
Fallick ml., McDermott D.F., LaRock D., Long J.P., Atkins M.B. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma J Urol 1997 ;  158 : 1691-1695 [cross-ref]
Slaton J.W., Perrotte P., Balbay M.D. Reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma J Urol 2000 ;  163 : 79
Han K.R., Pantuck A.J., Bui M.H., Shvarts O., Freitas D.G., Zisman A., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma Urology 2003 ;  61 : 314-319 [inter-ref]
Margulis V., Matin S.F., Wood C.G. Cytoreductive nephrectomy in metastatic renal cell carcinoma Curr Opin Urol 2008 ;  18 : 474-480 [cross-ref]
Rini B.I., Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 2007 ;  177 : 1978-1984 [cross-ref]
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear cell renal cell carcinoma N Engl J Med 2007 ;  356 : 125-134 [cross-ref]
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma N Engl J Med 2007 ;  356 : 115-124 [cross-ref]
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R.A., Kapoor A., et al. Temsirolimus, interferon alpha, or both for advanced renal cell carcinoma N Engl J Med 2007 ;  356 : 2271-2281 [cross-ref]
Zini L., Capitanio U., Perrotte P., Jeldres C., Shariat S.F., Arjane P., et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma Urology 2009 ;  73 : 342-346 [cross-ref]
Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., Brady M.S. Resection of metastatic renal cell carcinoma J Clin Oncol 1998 ;  16 : 2261-2266 [cross-ref]
Van Der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., Bex A., de Gast G., Haanen J.B., Boven E. Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 2008 ;  14 : 2431-2436 [cross-ref]
Shuch B., Riggs S.B., LaRochelle J.C., Kabbinavar F.F., Avakian R., Pantuck A.J., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 2008 ;  102 : 692-696 [cross-ref]






© 2010 
Elsevier Masson SAS. Tous droits réservés.